Germfree's Development of AirV2

Germfree is a US manufacturer of biocontainment laboratories and other critical environments.

Established in 1962, our facilities and equipment are deployed in major healthcare systems, universities and the biotech sector, with clients ranging from the NIH to NASA. In January 2020, a Germfree-built, high containment laboratory in Singapore was the first in the region to isolate SARS-CoV-2 (COVID-19).

Early in the pandemic, we conducted a comprehensive risk assessment of our facilities and onsite workforce. We initiated the recommended protocols to keep our people safe. However, our site analysis indicated that an added layer of protection was needed for some indoor spaces, primarily the open office areas and conference rooms. We determined that by adding air filtration units, we could further reduce the risk of airborne transmission of the coronavirus.

Germfree’s products are geared for complex, critical or controlled environments. We looked for a ‘right-fit’ commercial air filtration system designed for large office areas. None of the off-the-shelf machines met our requirements. Germfree’s biosafety engineers and R&D team applied their expertise to create AirV2.